About the Company
Millendo Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MLND News
Millendo Therapeutics (NASDAQ:MLND) Will Have To Spend Its Cash Wisely
Given this risk, we thought we'd take a look at whether Millendo Therapeutics (NASDAQ:MLND) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the ...
Global Congenital Adrenal Hyperplasia Treatment Market Poised for Significant Growth, Reaching US$ 892 Million by 2033
Congenital Adrenal Hyperplasia Treatment Market is anticipated to soar to US$ 892 million by 2033 projecting a CAGR of 8.1%.
Tempest and Millendo Announce Stockholder Approval of Merger
About Millendo Therapeutics, Inc. Millendo Therapeutics is a biopharmaceutical company previously primarily focused on developing novel treatments for endocrine diseases where current therapies do ...
David M Mott's Net Worth
Who is David M Mott? David M Mott has an estimated net worth of $2.21 Billion. This is based on reported shares across multiple companies, which include PhaseBio Pharmaceuticals Inc, Ra ...
Peter W. Sonsini's Net Worth
Who is Peter W. Sonsini? Peter W. Sonsini has an estimated net worth of $898 Million. This is based on reported shares across multiple companies, which include Desktop Metal, Inc., Cascadian ...
ATXS Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.
Intellia Therapeutics Inc NTLA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
FULC Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high ...
Outlook Therapeutics, Inc. (OTLK)
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of ...
Cargo Therapeutics Inc CRGX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Revance Therapeutics, Inc. (RVNC)
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript February 29, 2024 Revance Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
Fate Therapeutics, Inc.
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno ...
Loading the latest forecasts...